{"url_path":"/sec/mygn/8-k/2026-06-23/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/899923/0000899923-26-000062-index.html","accession_number":"0000899923-26-000062","cik":"0000899923","ticker":"MYGN","issuer_name":"MYRIAD GENETICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/899923/0000899923-26-000062-index.html","primary_entity_key":"0000899923","primary_entity_name":"MYRIAD GENETICS INC"},"word_count":127,"has_tables":true,"body_markdown":"ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers\n\nOn June 17, 2026, Daniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”) notified the Company that he is resigning as a director, effective immediately. Dr. Skovronsky’s resignation was not a result of any disagreement with the Company or due to any matter relating to the Company’s operations, policies, or practices.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nMYRIAD GENETICS, INC.\n\nDate: June 23, 2026By:/s/ Benjamin R. Wheeler\n\nBenjamin R. Wheeler\n\nChief Financial Officer"}